Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - July 2014


Biochemical Assays for Screening Workshop

09 Jul 2014 - 11 Jul 2014 - Hamburg, Germany



Bookmark and Share


Taking place over three days at the European ScreeningPort facility in Hamburg, the workshop will offer attendees the chance to participate in practical sessions using the latest technology available from the top screening equipment / reagent vendors in the pharmaceutical industry.

This is a must-attend event for anyone in the drug discovery industry to learn about screening technologies and discover what they can do for your company or laboratory.

Who should attend

• Scientists at all levels (undergraduates, postgraduates and laboratory based scientists within academic and industrial research organisations) who are engaged in early stage drug discovery and have an interest in the development, validation and utilisation of biochemical assays for screening against small molecule libraries.

• The course will include a series of lectures describing the screening compatible biochemical assays for use in drug discovery.

• The majority of the course will be laboratory based in which assays for targets that are currently actively being pursued for drug discovery purposes (kinases, histone deacetylases and proteases) will be developed, validated and screened against a small molecule library (known drugs). Selected Hit compounds will be evaluated in suitable Secondary assays.

Expected outcomes from the workshop

It is envisaged that upon completion of the course, attendees will have gained an insight into the key parameters to be considered when developing biochemical assays and performing small molecule screening, data analysis and validation of Hits in suitable Secondary assays.

Agenda Topics

•    Km Determination for Substrates
•    Aspects of Adaption of Assays for Screening of a Small Molecule Library (Known Drugs)
•    Choice of Biochemical Assay Development Projects: Kinase, Protease or Histone Deacetylase
•    Data Analysis and Classifying Compounds as Hits
•    IC50 Determination for Inhibitor, Signal Stability, Choice of Liquid Handling and Z’
•    Interferers
•    Kinetic Characterisation of Enzymes
•    Validation of Hits Selected from Screening Campaigns



Further information
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!